- Home
- ATEX vs URGN Comparison
ATEX vs URGN Comparison
Compare ATEX & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATEX | URGN |
|---|---|---|
| Founded | 1997 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2014 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ATEX | URGN |
|---|---|---|
| Price | $74.41 | $33.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $50.00 | $29.29 |
| AVG Volume (30 Days) | 476.7K | ★ 569.0K |
| Earning Date | 02-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.85 | N/A |
| Revenue | ★ $6,031,000.00 | $1,128,000.00 |
| Revenue This Year | $2.70 | $129.09 |
| Revenue Next Year | $10.04 | $70.96 |
| P/E Ratio | $20.49 | ★ N/A |
| Revenue Growth | ★ 43.90 | N/A |
| 52 Week Low | $17.58 | $12.73 |
| 52 Week High | $88.12 | $33.40 |
Technical Indicators
Market Signals| Indicator | ATEX | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 61.07 | 71.52 |
| Support Level | $21.00 | $18.58 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 6.15 | 1.67 |
| MACD | 0.33 | 0.40 |
| Stochastic Oscillator | 46.42 | 88.77 |
Price Performance
Historical ComparisonAbout ATEX Anterix Inc.
Anterix Inc is a United States-based company engaged in delivering broadband needed to modernize infrastructure for energy, transportation, logistics, and other industries. The company offers Private LTE for utilities which help to automate processes, monitor environmental conditions, enable artificial intelligence, and drive productivity.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.